6499 Stock Overview
Engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medeon Biodesign, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$46.80 |
| 52 Week High | NT$55.00 |
| 52 Week Low | NT$39.45 |
| Beta | 0.71 |
| 11 Month Change | 1.74% |
| 3 Month Change | 13.87% |
| 1 Year Change | -3.21% |
| 33 Year Change | -9.70% |
| 5 Year Change | -12.35% |
| Change since IPO | -51.79% |
Recent News & Updates
Shareholder Returns
| 6499 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -1.2% | -1.5% | -2.4% |
| 1Y | -3.2% | 9.7% | 36.2% |
Return vs Industry: 6499 underperformed the TW Medical Equipment industry which returned 9.7% over the past year.
Return vs Market: 6499 underperformed the TW Market which returned 36.2% over the past year.
Price Volatility
| 6499 volatility | |
|---|---|
| 6499 Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.9% |
Stable Share Price: 6499 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6499's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Yue-Teh Jang | www.medeonbio.com |
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical device contract manufacturing, equity investment and commerce of medical devices, manufacturing and sale of injection molding and components of medical devices.
Medeon Biodesign, Inc. Fundamentals Summary
| 6499 fundamental statistics | |
|---|---|
| Market cap | NT$4.31b |
| Earnings (TTM) | -NT$810.63m |
| Revenue (TTM) | NT$211.86m |
20.4x
P/S Ratio-5.3x
P/E RatioIs 6499 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6499 income statement (TTM) | |
|---|---|
| Revenue | NT$211.86m |
| Cost of Revenue | NT$193.79m |
| Gross Profit | NT$18.08m |
| Other Expenses | NT$828.71m |
| Earnings | -NT$810.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | -8.80 |
| Gross Margin | 8.53% |
| Net Profit Margin | -382.62% |
| Debt/Equity Ratio | 0% |
How did 6499 perform over the long term?
See historical performance and comparison